| General Information | |
|---|---|
| ZINC ID | ZINC000003947920 |
| Molecular Weight (Da) | 432 |
| SMILES | N#Cc1ccc(CNC(=O)c2cnc(Nc3cccc(Cl)c3)nc2C(F)(F)F)cc1 |
| Molecular Formula | C20Cl1F3N5O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 105.389 |
| HBA | 4 |
| HBD | 2 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 30 |
| LogP | 4.828 |
| Activity (Ki) in nM | 218.776 |
| Polar Surface Area (PSA) | 90.7 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.13533484 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.1 |
| Ilogp | 2.96 |
| Xlogp3 | 4.12 |
| Wlogp | 5.69 |
| Mlogp | 2.55 |
| Silicos-it log p | 4.41 |
| Consensus log p | 3.95 |
| Esol log s | -5.09 |
| Esol solubility (mg/ml) | 3.47E-03 |
| Esol solubility (mol/l) | 8.04E-06 |
| Esol class | Moderately |
| Ali log s | -5.73 |
| Ali solubility (mg/ml) | 8.02E-04 |
| Ali solubility (mol/l) | 1.86E-06 |
| Ali class | Moderately |
| Silicos-it logsw | -8.62 |
| Silicos-it solubility (mg/ml) | 1.02E-06 |
| Silicos-it solubility (mol/l) | 2.37E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.01 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 2.81 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.311 |
| Logd | 3.713 |
| Logp | 4.048 |
| F (20%) | 0.001 |
| F (30%) | 0.002 |
| Mdck | 1.78E-05 |
| Ppb | 0.9921 |
| Vdss | 1.112 |
| Fu | 0.008 |
| Cyp1a2-inh | 0.772 |
| Cyp1a2-sub | 0.733 |
| Cyp2c19-inh | 0.935 |
| Cyp2c19-sub | 0.063 |
| Cl | 5.625 |
| T12 | 0.282 |
| H-ht | 0.99 |
| Dili | 0.928 |
| Roa | 0.859 |
| Fdamdd | 0.957 |
| Skinsen | 0.386 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.927 |
| Bcf | 1.075 |
| Igc50 | 3.903 |
| Lc50 | 5.463 |
| Lc50dm | 6.764 |
| Nr-ar | 0.14 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.913 |
| Nr-aromatase | 0.942 |
| Nr-er | 0.406 |
| Nr-er-lbd | 0.007 |
| Nr-ppar-gamma | 0.302 |
| Sr-are | 0.533 |
| Sr-atad5 | 0.022 |
| Sr-hse | 0.021 |
| Sr-mmp | 0.802 |
| Sr-p53 | 0.709 |
| Vol | 394.357 |
| Dense | 1.093 |
| Flex | 21 |
| Nstereo | 0.286 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 1 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 2 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 3 |
| Qed | 2 |
| Synth | 0.65 |
| Fsp3 | 2.857 |
| Mce-18 | 0.1 |
| Natural product-likeness | 20 |
| Alarm nmr | -1.772 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Accepted |
| Goldentriangle | Rejected |